Načítá se...
PF-06649751 efficacy and safety in early Parkinson’s disease: a randomized, placebo-controlled trial
BACKGROUND: PF-06649751 is a novel, oral, non-catechol-based, D1/D5 dopamine receptor partial agonist under investigation for the treatment of motor symptoms associated with Parkinson’s disease. METHODS: A 15-week, phase II, double-blind, placebo-controlled clinical trial was conducted to assess the...
Uloženo v:
| Vydáno v: | Ther Adv Neurol Disord |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7066585/ https://ncbi.nlm.nih.gov/pubmed/32201505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420911296 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|